PMID- 34595405
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211002
IS  - 2590-0048 (Electronic)
IS  - 2590-0048 (Linking)
VI  - 1
IP  - 1
DP  - 2019 Mar
TI  - Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: 
      Allogeneic Hematopoietic Cell Transplantation and Novel Therapies.
PG  - 2-9
LID - 10.2991/chi.d.190218.001 [doi]
AB  - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive 
      hematologic malignancy derived from precursors of plasmacytoid dendritic cells. 
      There is no established standard therapy for BPDCN and the efficacy of 
      conventional chemotherapy is limited, with an anticipated median overall survival 
      ranging from 8 to 14 months. No randomized controlled trials have ever been 
      performed to evaluate the benefit of frontline consolidation with an allogeneic 
      hematopoietic cell transplant (allo-HCT) in BPDCN. Yet, offering an allograft has 
      become the de facto option in BPDCN, and remains the only known long-term 
      curative option for these patients, even in the modern era of targeted therapies. 
      In our opinion, allo-HCT is recommended as part of frontline consolidation, 
      especially in patients achieving first complete remission and who are deemed 
      capable of tolerating the procedure, as published data show 3- to 4-year 
      progression-free survival ranging from 69% to 74% in this population. Prompt 
      referral to a transplant center, at the time of a diagnosis of BPDCN, is 
      important to confirm allo-HCT candidacy and to initiate the process of 
      identifying a suitable human leukocyte antigen (HLA)-compatible donor. Because 
      disease relapse remains a major concern, additional strategies, such as 
      post-allograft consolidation/maintenance therapy, are certainly needed to help 
      further improve outcomes. Finally, patients deemed ineligible to receive an 
      allo-HCT, due to lack of response and/or poor performance status, should be 
      considered for enrollment in clinical trials.
CI  - (c) 2019 International Academy for Clinical Hematology. Publishing services by 
      Atlantis Press International B.V.
FAU - Kharfan-Dabaja, Mohamed A
AU  - Kharfan-Dabaja MA
AD  - Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo 
      Clinic, Jacksonville, FL, USA.
FAU - Pemmaraju, Naveen
AU  - Pemmaraju N
AD  - Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
FAU - Mohty, Mohamad
AU  - Mohty M
AD  - Hopital Saint-Antoine, Universite Pierre & Marie Curie, INSERM UMRs U938, Paris, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190318
PL  - England
TA  - Clin Hematol Int
JT  - Clinical hematology international
JID - 101759455
PMC - PMC8432376
OTO - NOTNLM
OT  - Allogeneic hematopoietic cell transplant
OT  - Blastic plasmacytoid dendritic cell neoplasm
OT  - Overall survival
OT  - Targeted therapies
COIS- Mohamed A. Kharfan-Dabaja: Member of the speaker's bureau for Alexion 
      Pharmaceuticals, Seattle Genetics and Incyte; Naveen Pemmaraju: Research 
      funding/consulting: Stemline, Cellectis, Affymetrix, abbvie, Plexxikon. Mohamad 
      Mohty: Consultancy for Servier
EDAT- 2019/03/18 00:00
MHDA- 2019/03/18 00:01
PMCR- 2019/03/18
CRDT- 2021/10/01 07:39
PHST- 2019/01/02 00:00 [received]
PHST- 2019/02/18 00:00 [accepted]
PHST- 2021/10/01 07:39 [entrez]
PHST- 2019/03/18 00:00 [pubmed]
PHST- 2019/03/18 00:01 [medline]
PHST- 2019/03/18 00:00 [pmc-release]
AID - CHI-1-1-2 [pii]
AID - 10.2991/chi.d.190218.001 [doi]
PST - epublish
SO  - Clin Hematol Int. 2019 Mar 18;1(1):2-9. doi: 10.2991/chi.d.190218.001. 
      eCollection 2019 Mar.